EUVIMEDSkopri EUVIMED
Crossref

Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy

Guy A MacGowan iD, Julie Samuel, Adam McDiarmid, Oscar Gonzalez-Fernandez iD, Gareth Parry

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15419 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Guy A MacGowan and 4 co-authors. Institution: Cardiothoracic Board, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK. Major MEDLINE topics: Heart Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Antiviral Agents. Cited 1 times so far (Crossref); 10 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Purpose

The aim of the study was to determine outcomes after heart transplantation for cytomegalovirus (CMV) mismatched patients (D + /R − ) who underwent a surveillance and preemptive therapy protocol, compared to nonmismatch patients.

Methods

A review of patient records from January 2010 to December 2020 with follow‐up to October 2023 was done. The protocol consisted weekly surveillance with CMV PCR starting 4 weeks after transplant continuing up until the patient seroconverts or up to 3 months posttransplant if the patient does not seroconvert. Valganciclovir was given for 2 weeks to those who seroconverted.

Results

Two hundred and twenty‐one patients were included, and 23% were mismatched patients. Overall survival was not different between CMV groups ( p = NS). Causes of death and morbidities were also not significantly different ( p = NS). Sixty‐six percent of mismatch patients seroconverted, and there was also a significantly older donor age in the seroconverted patients compared to nonseroconverted patients (41 ± 11 vs. 29 ± 12 years, p < 0.005), indicating a higher risk donor profile. A multivariate Cox regression including donor age showed that there was no increase in mortality in the seroconverted mismatches compared to nonmismatch patients ( p = NS).

Conclusions

There is no significant increased mortality or morbidity using a CMV surveillance and preemptive therapy protocol. The effect of donor age on seroconversion of mismatches requires further validation.

Subjects

MeSH terms (MEDLINE)

Heart TransplantationCytomegalovirus InfectionsCytomegalovirusAntiviral AgentsGraft SurvivalHumansFemaleMaleFollow-Up StudiesAdultPrognosisRetrospective StudiesRisk FactorsGraft RejectionSurvival RateMiddle AgedPostoperative ComplicationsTissue Donors

Author keywords

CMVheart transplantoutcomes

Substances

Antiviral Agents

Authors and institutions

  • Cardiothoracic Board, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK.
  • Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Department of Microbiology, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK.

ORCID profiles: Guy A MacGowan, Oscar Gonzalez-Fernandez

Cite

APA

MacGowan, G. A., Samuel, J., McDiarmid, A., Gonzalez-Fernandez, O., & Parry, G. (2024). Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy. Clinical Transplantation. https://doi.org/10.1111/ctr.15419

Vancouver

MacGowan GA, Samuel J, McDiarmid A, Gonzalez-Fernandez O, Parry G. Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy. Clinical Transplantation. 2024. doi:10.1111/ctr.15419

BibTeX
@article{MacGowan2024,
  author = {MacGowan, Guy A and Samuel, Julie and McDiarmid, Adam and Gonzalez-Fernandez, Oscar and Parry, Gareth},
  title = {Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15419}
}
Start for free →